DefiniGEN – Parkwalk closes follow on investment

By |April 21st, 2016|

Parkwalk closes DefiniGen investment for the University of Cambridge Enterprise Fund IV and Parkwalk Funds

DefiniGEN, a spin-out from the University of Cambridge Regenerative Medicine Department at Addenbrooke’s Hospital, have created a stem cell technology to provide human cells to the drug discovery sector for use in lead optimisation and toxicity programmes.

The Company’s proprietary production […]